GENA-104 ADC / Genome & Company - LARVOL DELTA

Preclinical development of GENA-104 ADC, an exatecan-based novel antibody-drug conjugate targeting CNTN4, for solid tumors (AACR 2026) - "Taken together, these findings support the therapeutic potential of GENA-104 ADC as a targeted treatment strategy for CNTN4-expressing solid tumors. This research represents a meaningful step toward the development of precision oncology therapeutics that may offer improved outcomes for patients with limited treatment options."

ADC • Preclinical • Endometrial Cancer • Fibrosarcoma • Genito-urinary Cancer • Hepatocellular Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Prostate Cancer • Sarcoma • Solid Tumor • APP • CNTN